The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Heart J
Main Authors: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Basic Science
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://ncbi.nlm.nih.gov/pubmed/28637178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares